Epstein-Barr Virus Genome Replication as a Molecular Target for Cancer Therapy

DOI Web Site Web Site PubMed 14 References
  • Noguchi Kohji
    Division of Chemotherapy, Faculty of Pharmacy, Keio University

Bibliographic Information

Other Title
  • EBVのウイルスゲノム複製を標的とした分子標的研究
  • Symposium Review EBVのウイルスゲノム複製を標的とした分子標的研究
  • Symposium Review EBV ノ ウイルスゲノム フクセイ オ ヒョウテキ ト シタ ブンシ ヒョウテキ ケンキュウ

Search this article

Abstract

<p>Epstein-Barr virus (EBV), a human oncogenic virus, is a B cell-tropic herpesvirus and has the ability to immortalize normal B cells during latent infection. The Epstein-Barr nuclear antigen 1 (EBNA1) protein of EBV is expressed in the most EBV latently infected cells and binds to a specific viral genome region termed “oriP” (origin of plasmid replication) to maintain the stability of the approximately 170 kb double-stranded circular virus genomic DNA (episome) in cells. EBV elimination is thought to inhibit progression of EBV-associated malignancies, and the EBNA1-dependent mechanisms for EBV episome replication and maintenance are considered to be novel molecular targets for anti-EBV therapy. We have explored small-molecule compounds that can inhibit the binding between EBNA1 protein and oriP and found one pyrrole imidazole polyamide named DSE3 which can also inhibit EBV-mediated immortalization of normal B cells. These data suggested that an EBNA1-targeting strategy could be useful to combat EBV-associated malignancies.</p>

Journal

  • YAKUGAKU ZASSHI

    YAKUGAKU ZASSHI 139 (1), 63-67, 2019-01-01

    The Pharmaceutical Society of Japan

References(14)*help

See more

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top